Qiagen debuts solution for SARS-CoV-2 T-cell research

2019 11 19 19 30 0103 T Cell 400

Qiagen has launched the QuantiFeron SARS-CoV-2 Research Use Only (RUO) solution to detect T-cell responses to the novel coronavirus. The solution could aid researchers in investigating the cause, spread, and control of COVID-19.

QuantiFeron SARS-CoV-2 ROU is a modular system based on the platform Qiagen developed for its QuantiFeron-TB Gold Plus test for latent tuberculosis.

Potential uses of the system include determining how long T-cell response and any associated SARS-CoV-2 immunity lasts. Researchers could also study whether T-cell response can indicate disease severity, the company noted.

QuantiFeron SARS-CoV-RUO is the latest addition to Qiagen's COVID-19 portfolio of products. Other COVID-19 solutions include sample-preparation technology and tests for SARS-CoV-2 infection, antibodies, and antigens.

Page 1 of 3
Next Page